Medtronic PLC to Issue Quarterly Dividend of $0.71 (NYSE:MDT)

Medtronic PLC (NYSE:MDT) announced a quarterly dividend on Thursday, March 5th. Shareholders of record on Friday, March 27th will be paid a dividend of 0.71 per share by the medical technology company on Friday, April 17th. This represents a c) annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, March 27th.

Medtronic has increased its dividend by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 49 years. Medtronic has a dividend payout ratio of 47.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Medtronic to earn $5.83 per share next year, which means the company should continue to be able to cover its $2.84 annual dividend with an expected future payout ratio of 48.7%.

Medtronic Price Performance

NYSE:MDT opened at $92.96 on Friday. The company has a market cap of $119.35 billion, a P/E ratio of 25.89, a P/E/G ratio of 2.40 and a beta of 0.71. The firm’s fifty day moving average price is $98.80 and its two-hundred day moving average price is $96.95. Medtronic has a one year low of $79.55 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the business posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic will post 5.46 earnings per share for the current year.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved a cash dividend of $0.71 for Q4 FY2026, reinforcing Medtronic’s long track record as a dividend grower and supporting income‑focused investor demand. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, expanding its connected diabetes portfolio and addressing long‑term growth in continuous glucose monitoring and smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Medtronic and GE HealthCare expanded their patient‑monitoring alliance, which could broaden distribution for products like Nellcor pulse oximetry and support recurring revenue streams. Medtronic, GE HealthCare expand patient monitoring alliance
• Positive Sentiment: Industry reports continue to rank Medtronic among leaders in biosensors and continuous glucose monitoring, supporting the company’s strategic position in a fast‑growing addressable market. Biosensors Company Evaluation Report 2025
• Neutral Sentiment: MiniMed priced its IPO at $20.00 per share for 28,000,000 shares — a procedural step that establishes a public valuation for the diabetes unit but doesn’t by itself show how Medtronic will deploy proceeds or adjust ownership. MiniMed announces pricing of initial public offering
• Negative Sentiment: MiniMed’s US IPO raised roughly $560 million — the market is interpreting the spin‑out as a catalyst for MDT selling pressure because it shifts future diabetes growth and cash flows away from the parent and may prompt portfolio rebalancing by investors. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).